This inclusive text describes 3D Printing for pharmaceutical applications, including emerging 3D technologies. The book focuses on the functionality of the materials/biomaterials used for the preparation of dosage forms and devices, fundamentals for preparing these systems and novel applications using these additive manufacturing techniques. Also, the text includes clinical relevance and regulatory considerations for the future of personalized medicine.
Authored by experts with a broad range of experience, extensive insight into the science of 3D printing technology used to produce these systems is provided. Highlighting viewpoints from the academic, polymer excipient, equipment, product development and regulatory communities, this comprehensive text compiles input from industry thought leaders to illustrate strategies and technologies for applying techniques of additive manufacturing for drug product and device development whilealso providing insight into the path forward for the technology in years to come.

Covers regulatory and manufacturing aspects of 3D printing in drug development Particular focus on hot melt extrusion and extruded filaments suitable for optimizing 3D printing Thorough short text and guide for use on the production line of 3D printing of pharmaceuticals

Autorentext

Dr. Michael A. Repka is Distinguished Professor of the Department of Pharmaceutics at The University of Mississippi. He is also Founder and Director of the Pii Center for Pharmaceutical Technology. His research interests include the solubilization and delivery of poorly soluble bioactives via Hot Melt Extrusion (HME) technology, while coupling HME techniques with 3D printing to produce patient centric delivery systems . Dr. Repka has established himself as an expert in this major pharmaceutical processing field through his numerous peer-reviewed publications, presentations and scientific talks.
Dr. Nigel Langley is currently the Global Technical Director, Life Sciences at Gaylord Chemical LLC. He has a strong interest in excipient innovation, solubilization, hot melt extrusion and 3D printing. Dr. Langley has also worked at BASF and Croda International PLC and is the current Chair of IPEC-Americas.

Klappentext

Overview of Pharmaceutical 3D Printing Technologies.- Clinical Benefit of 3D Printed Products.- Characterization or Quality Control of 3D Printed Products.- Polymers for HME based 3D Printing.- Cellulosic Polymers.- API and Polymer Selection Formulation and Process Variables.- Fused Deposition Modeling 3D Printing.-Semi-solid Extrusion Printing and 3D.- Future Trends Including Novel Polymeric Excipients Designed for Purpose Bioprinting.

Inhalt
Overview of Pharmaceutical 3D Printing Technologies.- Clinical Benefit of 3D Printed Products.- Characterization or Quality Control of 3D Printed Products.- Polymers for HME based 3D Printing.- Cellulosic Polymers.- API and Polymer Selection Formulation and Process Variables.- Fused Deposition Modeling 3D Printing.-Semi-solid Extrusion Printing and 3D.- Future Trends Including Novel Polymeric Excipients Designed for Purpose Bioprinting.